CN 

Overview

Xiaoxue Weng practices practicing medicine in China.

Their clinical expertise encompasses Chronic Kidney Disease and End-Stage Renal Disease (ESRD).

They are actively involved in clinical research, co-authoring 8 peer reviewed articles.

Locations

China
Other Locations
Fuzhou, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


Frequently Asked Questions about Xiaoxue Weng

Is Xiaoxue Weng a top-rated expert for Chronic Kidney Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Xiaoxue Weng is classified as an Experienced expert for Chronic Kidney Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Xiaoxue Weng participate in research or clinical trials?

Yes. Xiaoxue Weng has published 8 articles and abstracts on conditions like Chronic Kidney Disease. You can view a list of Xiaoxue Weng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Weng's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile